Despite recent advances in our understanding of the biological basis of prostate cancer, the management
of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the
phosphatidylinositol 3-kinase (PI3K) pathway is increasingly implicated in a number of malignancies, including prostate
carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the therapeutic
implications of targeting it.
Keywords: Androgen receptor, mammalian target of rapamycin, phosphatidylinositol 3-kinase, prostate cancer, PTEN.
Rights & PermissionsPrintExport